SCHEMBL8367146

SCHEMBL8367146

CCOC(=O)c1coc(N(S(C)(=O)=O)S(C)(=O)=O)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
NLRP3 Q96P20 1/20 0.41
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 2/20 0.37
TP53 P04637 2/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TLR9 Q9NR96 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FBP1 P09467 1/20 0.37
GLP1R P43220 1/20 0.36
HPGD P15428 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351523 0.87 CYP1A2 (0.43) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL28374254 0.78 CYP1A2 (0.47) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL160214 0.77 CYP1A2 (0.53) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL15888607 0.76 CYP1A2 (0.43) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL2070169 0.75 CYP1A2 (0.55) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL3349539 0.74 NLRP3 (0.52) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL2077461 0.74 CYP1A2 (0.41) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL12489972 0.74 CYP1A2 (0.41) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL15888647 0.74 NLRP3 (0.41) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL31412793 0.73 CYP1A2 (0.53) CYP1A2NLRP3MAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-7312360-B2 Substituted hydroxyethylamines ELAN PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-7312360-B2 Substituted hydroxyethylamines ELAN PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
WO-2003050073-A1 SUBSTITUTED HYDROXYETHYLAMINES ELAN PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME CYP1A2 534/4885NLRP3 4217/4885MAPT 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.